Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional

Add Glucokinase Activator to Target A1c

ClinicalTrials.gov ID: NCT02405260

Public ClinicalTrials.gov record NCT02405260. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 7, 2026, 12:12 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multi-Center, Adaptive Phase 2, Randomized, Double-Blind, Placebo- and Active-Controlled (Sitagliptin), Parallel Group Study to Evaluate the Safety and Efficacy of TTP399 Following 6 Months Administration in Subjects With Type 2 Diabetes Mellitus on A Stable Dose of Metformin

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This trial is a multi-center, adaptive, randomized, double-blind, placebo- and active- controlled, parallel group, Phase 2 study in subjects with T2DM to evaluate the effect of TTP399 on HbA1c following administration for 6 months.

Study identification

NCT ID
NCT02405260
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
vTv Therapeutics
Industry
Enrollment
190 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years to 75 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Feb 28, 2015
Primary completion
Jun 30, 2016
Completion
Aug 31, 2016
Last update posted
Feb 9, 2017

2015 – 2016

United States locations

U.S. sites
20
U.S. states
13
U.S. cities
19
Facility City State ZIP Site status
Not listed Mesa Arizona 85213
Not listed Tuscon Arizona 85741
Not listed Canoga Park California 91303
Not listed Huntington Park California 90255
Not listed Los Angeles California 90056
Not listed West Hills California 91307
Not listed Centennial Colorado 80112
Not listed Littleton Colorado 80127
Not listed Waterbury Connecticut 06708
Not listed West Palm Beach Florida 33409
Not listed Gurnee Illinois 60031
Not listed Evansville Indiana 47725
Not listed Rochester Minnesota 55905
Not listed Greensboro North Carolina 27408
Not listed Moncks Corner South Carolina 29461
Not listed San Antonio Texas 78209
Not listed San Antonio Texas 78229
Not listed Schertz Texas 78154
Not listed Norfolk Virginia 23507
Not listed Richland Washington 99352

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02405260, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Feb 9, 2017 · Synced Sep 7, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02405260 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →